Health Economics

Citations 1-10 of 98 total displayed.

Most recent content (1 Oct 2009):

CLINICAL
Medico-economic evaluation of infliximab in rheumatoid arthritis—prospective French study of a cohort of 635 patients monitored for two years

Jacques Sany, Jean-David Cohen, Christophe Combescure, Marie-Cécile Bozonnat, Françoise Roch-Bras, Georges Lafon, and Jean-Pierre Daurès
Rheumatology 2009; 48: 1236-1241. [Abstract] [Full Text]  

Past content (since Jan 2001):

CLINICAL
Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany

J. Zeidler, T. Mittendorf, G. Vahldiek, H. Zeidler, and S. Merkesdal
Rheumatology 2008; 47: 1527-1534. [Abstract] [Full Text]  

MATTERS ARISING
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

G. Kobelt
Rheumatology 2008; 47: 1589-1590. [Extract] [Full Text]  

MATTERS ARISING
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply

A. Wailoo, N. Bansback, and J. Chilcott
Rheumatology 2008; 47: 1590-a. [Extract] [Full Text]  

CLINICAL
The direct healthcare costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit

R. M. Ara, J. C. Packham, and K. L. Haywood
Rheumatology 2008; 47: 68-71. [Abstract] [Full Text]  

CLINICAL
An economic evaluation of three physiotherapy treatments for non-specific neck disorders alongside a randomized trial

M. Lewis, M. James, E. Stokes, J. Hill, J. Sim, E. Hay, and K. Dziedzic
Rheumatology 2007; 46: 1701-1708. [Abstract] [Full Text]  

EDITORIALS
30 million, around 10 000 ... and 18 ... Figuring out the optimal treatment for musculoskeletal conditions in the National Health Service

D. A. Isenberg
Rheumatology 2007; 46: 1219-1220. [Extract] [Full Text]  

BASIC SCIENCE
Interleukin (IL)-23 p19 expression induced by IL-1ß in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-B and AP-1 dependent pathway

F.-L. Liu, C.-H. Chen, S.-J. Chu, J.-H. Chen, J.-H. Lai, H.-K. Sytwu, and D.-M. Chang
Rheumatology 2007; 46: 1266-1273. [Abstract] [Full Text]  

CLINICAL
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom

M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout
Rheumatology 2007; 46: 1320-1328. [Abstract] [Full Text]  

CLINICAL
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons
Rheumatology 2007; 46: 1345-1354. [Abstract] [Full Text]  

[Next page] Pages: 1 2 3 4 5 6 7 8 9 10